期刊
ANNALS OF INTERNAL MEDICINE
卷 154, 期 10, 页码 680-+出版社
AMER COLL PHYSICIANS
DOI: 10.7326/0003-4819-154-10-201105170-00008
关键词
-
资金
- National Institutes of Health [R01 ES017876]
- Escher Project [T6-202]
- Top Institute Pharma
In randomized trials with subgroup analyses, the primary treatment or intervention of interest is randomized, but the secondary factors defining subgroups are not. This article clarifies when confounding is an issue in subgroup analyses. If investigators are interested simply in targeting subpopulations for intervention, control for confounding is not needed. If investigators are interested in intervening on the secondary factors that define the subgroups to increase the treatment effect or in attributing the subgroup differences to the secondary factors themselves, then confounding is relevant and must be controlled for. The authors demonstrate this point by using examples from published randomized trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据